ArticleResearch and practice in thrombosis and haemostasis2026
Analytical validity of the INNOVANCE Antithrombin assay for the measurement of antithrombin activity at fitusiran clinical decision points.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fitusiran is an antithrombin (AT)-lowering therapy for hemophilia A and B, with dosing individually adjusted to maintain AT activity between 15% and 35%. The therapy, therefore, requires an AT activity assay with high analytical sensitivity and precision, especially at the lower end of the measuring range (≤20%). Objectives: This study evaluated the analytical performance characteristics of the INNOVANCE Antithrombin assay at the low end of the measuring range and assessed equivalence between different analyzers. Methods: Performance data were generated on various analyzers from Siemens Healthineers according to Clinical and Laboratory Standards Institute guidelines, including limit of quantification (LoQ), interferences, and precision. System comparability was evaluated using samples from patients treated with fitusiran. Results: This study demonstrated high precision and reproducibility of results across reagent lots and systems with <10% coefficient of variation at 10% and 15% AT activity on all analyzers, except for the BCS XP system at the 10% AT level, with a repeatability coefficient of variation of 13.94%. Diluted control plasma showed similar precision characteristics to native samples and good recovery of expected AT value. Therapeutics potentially being used by the hemophilia population were demonstrated to not interfere with the assay. LoQ was shown to be ≤8.78% of normal on all analyzers. System comparability was confirmed with correlation coefficients of ≥0.997, slopes between 0.976 and 1.005, and intercepts between 0.5% and 2.1% of normal. Conclusion: The study confirms the INNOVANCE Antithrombin assay can precisely and reliably quantify AT activity at fitusiran clinical decision points and further supports its suitability for clinical management of people on fitusiran prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.